This study aimed to test the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as a monotherapy or in combination with PDR001 in HCC patients positive for FGFR4 and KLB (ClinicalTrials.gov Identifier: NCT02325739). Here, FGFR4 is linked to hepatocellular carcinoma.